Skip to main content
. 2024 Jul 17;8(18):4792–4802. doi: 10.1182/bloodadvances.2024013468

Figure 2.

Figure 2.

Outcomes of patients with MDS transplanted with PTCY vs ATG. (A) OS, (B) PFS, (C) GRFS, (D) RI, and (E) NRM of patients with MDS who received PTCY or ATG as GVHD prophylaxis for UD allo-HSCT and stratified by donor type (MUD vs MMUD). Numbers below the graph show the number of patients at risk.